116 related articles for article (PubMed ID: 28502555)
1. Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs.
Giuliani J; Bonetti A
Clin Lung Cancer; 2017 Sep; 18(5):e363-e365. PubMed ID: 28502555
[No Abstract] [Full Text] [Related]
2. Receipt of financial assistance for oral targeted therapy among older adults with advanced non-small cell lung cancer: A prospective cohort study.
Kumar A; Ragavan M; Velazquez AI; Zeng S; Wong ML
J Geriatr Oncol; 2024 Jun; 15(5):101746. PubMed ID: 38490915
[No Abstract] [Full Text] [Related]
3. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.
Zhao X; Suryawanshi S; Hruska M; Feng Y; Wang X; Shen J; Vezina HE; McHenry MB; Waxman IM; Achanta A; Bello A; Roy A; Agrawal S
Ann Oncol; 2017 Aug; 28(8):2002-2008. PubMed ID: 28520840
[TBL] [Abstract][Full Text] [Related]
4. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
Carbone DP; Reck M; Paz-Ares L; Creelan B; Horn L; Steins M; Felip E; van den Heuvel MM; Ciuleanu TE; Badin F; Ready N; Hiltermann TJN; Nair S; Juergens R; Peters S; Minenza E; Wrangle JM; Rodriguez-Abreu D; Borghaei H; Blumenschein GR; Villaruz LC; Havel L; Krejci J; Corral Jaime J; Chang H; Geese WJ; Bhagavatheeswaran P; Chen AC; Socinski MA;
N Engl J Med; 2017 Jun; 376(25):2415-2426. PubMed ID: 28636851
[TBL] [Abstract][Full Text] [Related]
5. Histologic Transformation in NSCLC with PD-1 therapy.
Nagasaka M; Pansare RS; Abdulfatah E; Guan H; Tranchida P; Gadgeel SM
J Thorac Oncol; 2017 Sep; 12(9):e133-e134. PubMed ID: 28502723
[No Abstract] [Full Text] [Related]
6. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.
Aguiar PN; Perry LA; Penny-Dimri J; Babiker H; Tadokoro H; de Mello RA; Lopes GL
Ann Oncol; 2017 Sep; 28(9):2256-2263. PubMed ID: 28633409
[TBL] [Abstract][Full Text] [Related]
7. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Tsai FP; Wu TW
Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108
[TBL] [Abstract][Full Text] [Related]
8. Current state of immunotherapy for non-small cell lung cancer.
Malhotra J; Jabbour SK; Aisner J
Transl Lung Cancer Res; 2017 Apr; 6(2):196-211. PubMed ID: 28529902
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the Lung.
Yuan Z; Fromm A; Ahmed KA; Grass GD; Yang GQ; Oliver DE; Dilling TJ; Antonia SJ; Perez BA
J Thorac Oncol; 2017 Sep; 12(9):e135-e136. PubMed ID: 28502722
[No Abstract] [Full Text] [Related]
10. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapies for Lung Cancer.
Gubens MA
J Natl Compr Canc Netw; 2017 May; 15(5S):692-695. PubMed ID: 28515246
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
Ramamurthy C; Godwin JL; Borghaei H
Curr Treat Options Oncol; 2017 Jun; 18(6):33. PubMed ID: 28534248
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Peters S; Gettinger S; Johnson ML; Jänne PA; Garassino MC; Christoph D; Toh CK; Rizvi NA; Chaft JE; Carcereny Costa E; Patel JD; Chow LQM; Koczywas M; Ho C; Früh M; van den Heuvel M; Rothenstein J; Reck M; Paz-Ares L; Shepherd FA; Kurata T; Li Z; Qiu J; Kowanetz M; Mocci S; Shankar G; Sandler A; Felip E
J Clin Oncol; 2017 Aug; 35(24):2781-2789. PubMed ID: 28609226
[TBL] [Abstract][Full Text] [Related]
17. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
Sharabi A; Kim SS; Kato S; Sanders PD; Patel SP; Sanghvi P; Weihe E; Kurzrock R
Oncologist; 2017 Jun; 22(6):631-637. PubMed ID: 28550027
[TBL] [Abstract][Full Text] [Related]
18. Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology.
Shah-Manek B; Galanto JS; Nguyen H; Ignoffo R
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S13-S20. PubMed ID: 28535103
[TBL] [Abstract][Full Text] [Related]
19. Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment.
Nakamagoe K; Moriyama T; Maruyama H; Yokosawa M; Hara T; Tanaka S; Fujimoto M; Tamaoka A
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1357-1358. PubMed ID: 28516380
[No Abstract] [Full Text] [Related]
20. Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events.
Imafuku K; Yoshino K; Yamaguchi K; Tsuboi S; Ohara K; Hata H
Case Rep Oncol; 2017; 10(1):296-300. PubMed ID: 28512413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
